Universal amplifier system for high-fidelity multi-modal biosignal recordings

描述（由申请人提供）：生物电信号的测量、监测和使用已经从心脏电活动的测量发展到涵盖从心脏、骨骼肌和平滑肌到脑和外周神经组织的组织。随着这一发展，专门设备的发展，以捕捉和解释这些微小的信号。然而，生物电信号测量的未来正朝着多个源和多个位置的测量和集成发展，这导致需要通过为特定信号设计的专用设备来集成信号和源的问题。为了克服这个问题，Refer 2 Input（R2 i）及其在印第安纳州普渡大学（IUPUI）的研究伙伴在重新分析测量和采集问题后设计了新型生物电压扩器系统。由此产生的通用可逆放大器系统发挥了模拟和数字世界的优势，以跨越所有生物电信号的范围，并具有重新聚焦特定信号的能力，而无需重新配置硬件。在这个STTR中，R2 i及其在IUPUI的研究合作伙伴将进一步开发这项技术并证明其可行性。第一阶段的具体目标是：1）开发和实施硬件平台; 2）开发和实施软件平台; 3）完成硬件和软件系统的体内确认。经过验证和测试的UIA系统将构成基础仪器基础，在此基础上，将在第二阶段开发多模态、多频率应用。该系统利用了UIA系统的硬件通用性和实时重聚焦能力，这是一个相当大的商业市场。该系统将简化研究和临床实验室的仪器需求，通过融合到单一的通用记录平台来降低成本。

DESCRIPTION (provided by applicant): The measurement, monitoring and use of bioelectric signals has evolved from the measurement of the electrical activity of the heart to encompass tissues ranging from cardiac, skeletal and smooth muscles, to brain and peripheral nerve tissues. Together with this development has been the evolution of specialized equipment to capture and interpret these minute signals. However, the future of bioelectric signals measurement is moving towards the measurement and integration of multiple sources, and multiple locations, which leads to the problem of the need to integrate signals and sources through specialized equipment designed for specific signals. To overcome this problem, Refer2Input (R2i) and its research partners at Indiana University Purdue University (IUPUI) designed novel bioelectric compander system following a reanalysis of the measurement and acquisition problem. The resulting Universal Invertible Amplifier system plays to the strengths of the analog and digital world to span the range of all bioelectric signals coupled with the ability o refocus to specific signals without hardware reconfiguration. In this STTR, R2i and its research partner at IUPUI will further develop this technology and demonstrate feasibility. Phase I Specific Aims are: 1) Develop and implement the hardware platform 2) Develop and implement the software platform and, 3) Complete in- vivo validation of the hardware and software system. The validated and tested UIA system will form the foundational instrumentation basis upon which a multi-modal, multi-frequency applications will be developed in Phase II. This system takes advantage of the universality of the hardware and the real-time refocus abilities of the UIA system, for which a considerable commercial market exists. The system will simplify the instrumentation needs of research and clinical laboratories, reducing costs through convergence to a single common recording platform.